Skip to main content

Advertisement

SpringerLink
Log in

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effect of excision repair cross-complementing group 1 (ERCC1) and X-ray cross-complementing group 1 (XRCC1) gene polymorphisms on treatment outcome in patients receiving oxaliplatin-based regimens for metastatic colorectal cancer.

Methods

Hundred and thirteen patients with a diagnosis of metastatic colorectal cancer were treated with oxaliplatin-based chemotherapy. ERCC1 codon 118C/T and XRCC1 codon 399A/G polymorphisms were tested by real-time polymerase chain reaction (RT-PCR) method in peripheral blood lymphocytes of these patients. Disease control rates and survivals were compared by types of genotypes.

Results

Analyses of the patterns of the polymorphism located at ERCC1 codon 118 showed that 55 (48.67%) patients were homozygous for C/C genotype, 15 (13.27%) were homozygous for the T/T genotype, and 43 (38.06%) were heterozygous for C/T genotype. Analyses of the polymorphism located at XRCC1 codon 399 showed that 61 (53.98%) patients were homozygous for A/A genotype, 13 (11.50%) were homozygous for the G/G genotype, and 39 (34.52%) were heterozygous for A/G genotype. After two cycles of chemotherapy, there was complete response (CR) in 1 patient, partial response (PR) in 24 patients, and stable disease (SD) in 56 patients. Altogether in 81 (71.68%) patients the disease was controlled after chemotherapy. Thirty-two (28.32%) patients showed disease progression. After adjusting for some clinical factors, both the ERCC1 polymorphism and the XRCC1 polymorphism lost their roles in predicting DCR (P = 0.662, P = 0.631) and MST (P = 0.692, P = 0.572). But the combination of ERCC1 and XRCC1 polymorphisms was significantly associated with DCR (P = 0.01) and MST (P = 0.000) independently.

Conclusions

This is the first study which showed that polymorphisms of ERCC1 and XRCC1, in combination not individually, were independent predictors for DCR and OS. This may contribute to the selection of patients who would benefit from oxaliplatin-based chemotherapy for metastatic colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365(9454):153–165

    Article  PubMed  Google Scholar 

  2. Midgley R, Kerr D (1999) Colorectal cancer. Lancet 353:391–399

    Article  CAS  PubMed  Google Scholar 

  3. Punt CJ (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15:1453–1459

    Article  CAS  PubMed  Google Scholar 

  4. Ries LAG, Melbert D, Krapcho M et al (2007) SEER Cancer Statistics Review, 1975–2004. National Cancer Institute, Bethesda, MD. Available at http://seer.cancer.gov/csr/1975_2004/. Accessed 15 November 2007

  5. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  6. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553–4560

    Article  CAS  PubMed  Google Scholar 

  7. Raymond E, Chaney SG, Taamma A et al (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053–1071

    Article  CAS  PubMed  Google Scholar 

  8. Raymond E, Faivre S, Chaney S et al (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227–235

    CAS  PubMed  Google Scholar 

  9. Rosell R, Mendez P, Isla D (2007) Platinum resistance related to a functional NER pathway. J Thorac Oncol 2(12):1063–1066

    Article  PubMed  Google Scholar 

  10. Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33(6):565–577

    Article  CAS  PubMed  Google Scholar 

  11. Fortini P, Pascucci B, Parlanti E et al (2003) The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 85(11):1053–1071

    Article  CAS  PubMed  Google Scholar 

  12. Horton JK, Watson M, Stefanick DF et al (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18(1):48–63

    Article  CAS  PubMed  Google Scholar 

  13. Yu JJ, Mu C, Lee KB et al (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res Genomics 382:13–20

    Article  CAS  Google Scholar 

  14. Sorenson MA, Kurland CG, Pederson S et al (1989) Codon usage determines translation rate in Escherichia coli. J Mol Biol 207:365–377

    Article  Google Scholar 

  15. Kimchi-Sarfaty C, Oh JM, Kim IW et al (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528

    Article  CAS  PubMed  Google Scholar 

  16. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291–1295

    Article  CAS  PubMed  Google Scholar 

  17. Sharma RA, Dianov GL (2007) Targeting base excision repair to improve cancer therapies. Mol Aspects Med 28(3–4):345–374

    Article  CAS  PubMed  Google Scholar 

  18. Kweekel DM, Gelderblom H, Guchelaar HJ et al (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90–105

    Article  CAS  PubMed  Google Scholar 

  19. Yu JJ, Lee KB, Mu C et al (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16:555–560

    CAS  PubMed  Google Scholar 

  20. Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Amamoto M (2008) ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 32:1091–1096

    CAS  PubMed  Google Scholar 

  21. Tibaldi C, Giovannetti E, Vasile E, Mey V et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in capecitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797–1803

    Article  CAS  PubMed  Google Scholar 

  22. Smith S, Su D, Rigault de la Longrais IA et al (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25(33):5172–5179

    Article  CAS  PubMed  Google Scholar 

  23. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin C, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism s a predictive factor for the tumor response to oxaliplatin/5-Xuorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11:6212–6217

    Article  CAS  PubMed  Google Scholar 

  24. Martinez-Balibrea E, Abad A, Aranda E et al (2008) Pharmacogenetic approach for capecitabine or 5-Xuorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44:1229–1237

    Article  CAS  PubMed  Google Scholar 

  25. Ruzzo A, Graziano F, Loupakis F et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25(10):1247–1254

    Article  CAS  PubMed  Google Scholar 

  26. Lindahl T, Lood RD (1999) Quality control by DNA repair. Science 286:1897–1905

    Article  CAS  PubMed  Google Scholar 

  27. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz H-J (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354

    CAS  PubMed  Google Scholar 

  28. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15:1049–1053

    Article  CAS  PubMed  Google Scholar 

  29. Colhoun HM, McKeigue PM, Davey Smith G et al (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:865–872

    Article  PubMed  Google Scholar 

  30. Huang ZH, Hua D, Du X et al (2009) Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64(5):1001–1007

    Article  CAS  PubMed  Google Scholar 

  31. Li WQ, Zhang L, Ma JL et al (2009) Association between genetic polymorphisms of DNA base excision repair genes and evolution of precancerous gastric lesions in a Chinese population. Carcinogenesis 30(3):500–505

    Article  PubMed  Google Scholar 

  32. Kim HS, Kim MK, Chung HH et al (2009) Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113:264–269

    Article  CAS  PubMed  Google Scholar 

  33. Improta G, Sgambato A, Bianchino G et al (2008) Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case–control study in a Southern Italian population. Anticancer Res 28(5B):2941–2946

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, The Affiliated Hospital of Medical College, Qing Dao University, 266003, Qingdao, China

    Jun Liang, Tao Jiang, Zi-min Liu, Hong-ying Lv & Wei-wei Qi

  2. Central Laboratory, The Affiliated Hospital of Medical College, Qing Dao University, 266003, Qingdao, China

    Ru-yong Yao

Authors
  1. Jun Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ru-yong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zi-min Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong-ying Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei-wei Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Liang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, J., Jiang, T., Yao, Ry. et al. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 66, 493–500 (2010). https://doi.org/10.1007/s00280-009-1186-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1186-3

Keywords

Search

Navigation